Compare BBBY & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBBY | REPL |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | 389 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.5M | 407.1M |
| IPO Year | N/A | 2018 |
| Metric | BBBY | REPL |
|---|---|---|
| Price | $4.91 | $10.51 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $8.00 | $5.67 |
| AVG Volume (30 Days) | 2.3M | ★ 3.2M |
| Earning Date | 04-27-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $1.50 |
| 52 Week High | $12.65 | $12.50 |
| Indicator | BBBY | REPL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Bed Bath & Beyond Inc is an e-commerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering products and services that enable its customers to enhance everyday life through quality, style, and value. The company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites, as well as a blockchain asset portfolio. Its e-commerce platforms, www.bedbathandbeyond.com and www.overstock.com, are targeted at customers seeking various products such as furniture, bedding, area rugs, tabletop and cookware, decor, storage, jewelry, etc, at affordable prices. In addition to products, the company also offers add-on services across platforms, including warranties, shipping insurance, and installation services.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.